Literature DB >> 28068238

Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors.

Andrew Y Lee1, Daniel W Golden1, Jose G Bazan2, Malgorzata Kopec1, Charles A Pelizzari1, Sonya Aggarwal3, Daniel T Chang3, Stanley L Liauw4.   

Abstract

PURPOSE: Pelvic bone marrow (BM) constraints may offer a means to reduce the toxicity commonly associated with chemoradiation for anal cancer. We conducted a bi-institutional analysis of dose-volume metrics in a time-sensitive fashion to devise practical metrics to minimize hematologic toxicity. METHODS AND MATERIALS: Fifty-six anal cancer patients from 2 institutions received definitive radiation therapy (median primary dose of 54 Gy) using intensity modulated radiation therapy (IMRT, n=49) or 3-dimensional (3D) conformal therapy (n=7) with concurrent 5-fluorouracil (5-FU) and mitomycin C. Weekly blood counts were retrospectively plotted to characterize the time course of cytopenias. Dose-volume parameters were correlated with blood counts at a standardized time point to identify predictors of initial blood count nadirs.
RESULTS: Leukocytes, neutrophils, and platelets reached a nadir at week 3 of treatment. Smaller volumes of the pelvic BM correlated most strongly with lower week 3 blood counts, more so than age, sex, body mass index (BMI), or dose metrics. Patients who had ≥750 cc of pelvic BM spared from doses of ≥30 Gy had 0% grade 3+ leukopenia or neutropenia at week 3. Higher V40 Gy to the lower pelvic BM (LP V40) also correlated with cytopenia. Patients with an LP V40 >23% had higher rates of grade 3+ leukopenia (29% vs 4%, P=.02), grade 3+ neutropenia (33% vs 8%, P=.04), and grade 2+ thrombocytopenia (32% vs 7%, P=.04) at week 3. On multivariate analysis, pelvic BM volume and LP V40 remained associated with leukocyte count, and all marrow subsite volumes remained associated with neutrophil counts at week 3 (P<.1).
CONCLUSIONS: Larger pelvic BM volumes correlate with less severe leukocyte and neutrophil nadirs, suggesting that larger total "marrow reserve" can mitigate cytopenias. Sparing a critical marrow reserve and limiting the V40 Gy to the lower pelvis may reduce the risk of hematologic toxicity.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28068238     DOI: 10.1016/j.ijrobp.2016.10.010

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  Dosimetric Comparison of Intensity-Modulated Proton Therapy and Volumetric-Modulated Arc Therapy in Anal Cancer Patients and the Ability to Spare Bone Marrow.

Authors:  Teresa Meier; Anthony Mascia; Eric Wolf; Jordan Kharofa
Journal:  Int J Part Ther       Date:  2017-12-28

2.  Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy.

Authors:  Corey C Foster; Andrew Y Lee; Larissa V Furtado; John Hart; Lindsay Alpert; Shu-Yuan Xiao; Neil H Hyman; Manish R Sharma; Stanley L Liauw
Journal:  PLoS One       Date:  2018-03-09       Impact factor: 3.240

3.  18F-FDG PET Predicts Hematologic Toxicity in Patients with Locally Advanced Anal Cancer Treated With Chemoradiation.

Authors:  John M David; Yong Yue; Kevin Blas; Andrew Hendifar; Peyman Kabolizadeh; Richard Tuli
Journal:  Adv Radiat Oncol       Date:  2019-07-04

4.  Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer.

Authors:  Martin P Nilsson; Anders Johnsson; Jonas Scherman
Journal:  Radiat Oncol       Date:  2021-08-16       Impact factor: 3.481

5.  Dosimetric parameters and absolute monocyte count can predict the prognosis of acute hematologic toxicity in cervical cancer patients undergoing concurrent chemotherapy and volumetric-modulated arc therapy.

Authors:  Xiaoyong Xiang; Zhen Ding; Qi Zeng; Lingling Feng; Chunyan Qiu; Dongjie Chen; Jiawei Lu; Ning Li
Journal:  Radiat Oncol       Date:  2022-03-05       Impact factor: 3.481

6.  Multi-institutional Comparison of Intensity Modulated Photon Versus Proton Radiation Therapy in the Management of Squamous Cell Carcinoma of the Anus.

Authors:  Jahan J Mohiuddin; Krishan R Jethwa; Nikhil Grandhi; William G Breen; Xingmei Wang; Akbar Anvari; Hui Lin; Harigopal Sandhyavenu; Abigail Doucette; John P Plastaras; William G Rule; James M Metz; Kenneth W Merrell; Terence T Sio; Jonathan B Ashman; Michael G Haddock; Edgar Ben-Josef; Christopher L Hallemeier; Andrzej P Wojcieszynski
Journal:  Adv Radiat Oncol       Date:  2021-06-24

7.  Impact of hematologic toxicities during concurrent chemoradiation for cervical cancer.

Authors:  Feiya Shi; Alison K Yoder; Claire Mach; Shraddha Dalwadi; Matthew L Anderson; Tracilyn R Hall; Michelle S Ludwig
Journal:  Obstet Gynecol Sci       Date:  2022-02-22

8.  Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer.

Authors:  Maxwell Robinson; Rebecca Muirhead; Clare Jacobs; Rosie Cooke; Kwun-Ye Chu; Frank Van den Heuvel; Stasya Ng; Pradeep Virdee; Victoria Strauss; Maria Hawkins
Journal:  Radiother Oncol       Date:  2019-09-07       Impact factor: 6.280

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.